Cat. No.: HY-B1127

Betamipron

(Synonyms: N-Benzoyl-β-alanine)

Customer Review

Based on 1 Customer Validation

Betamipron (N-benzoyl-β-alanine) is a carbapenem β-lactam antibiotic with antibacterial activity against most Gram-positive and Gram-negative aerobic and anaerobic bacteria. Betamipron can target and inhibit renal organic anion transporters, alleviate renal injury caused by Cisplatin (HY-17394), without interfering with the biological activity of cisplatin. Betamipron is often used in combination with panipenem, which can attenuate the renal effects induced by panipenem and slightly promote the proliferation of Clostridium difficile in the cecum. Betamipron can be used in studies related to renal injury and bacterial infection.

For research use only. We do not sell to patients.

Purity: 98.69%
CAS No.: 3440-28-6
Formula: C₁₀H₁₁NO₃
Molecular Weight:193.20

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Betamipron Chemical Structure

CAS No.: 3440-28-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

β-lactam

All Antibiotic Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	6 μM Compound: Betamipron	TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells	[PMID: 10991954]
S2	IC₅₀	39 μM Compound: Betamipron	TP_TRANSPORTER: inhibition of PHA uptake (PHA: 5uM) in hOAT1-expressing S2 cells TP_TRANSPORTER: inhibition of PHA uptake (PHA: 5uM) in hOAT1-expressing S2 cells	[PMID: 14978359]
S2	IC₅₀	47.5 μM Compound: Betamipron	TP_TRANSPORTER: inhibition of ES uptake (ES: 50nM) in rOAT3-expressing S2 cells TP_TRANSPORTER: inhibition of ES uptake (ES: 50nM) in rOAT3-expressing S2 cells	[PMID: 14978359]
S2	IC₅₀	483 μM Compound: Betamipron	TP_TRANSPORTER: inhibition of ES uptake (ES: 50nM) in hOAT4-expressing S2 cells TP_TRANSPORTER: inhibition of ES uptake (ES: 50nM) in hOAT4-expressing S2 cells	[PMID: 14978359]
S2	IC₅₀	9.92 μM Compound: Betamipron	TP_TRANSPORTER: inhibition of ES uptake (ES: 50nM) in hOAT3-expressing S2 cells TP_TRANSPORTER: inhibition of ES uptake (ES: 50nM) in hOAT3-expressing S2 cells	[PMID: 14978359]

In Vitro

Betamipron (1:1 ratio with panipenem) inhibits renal dehydropeptidase-I and kidney anion transport to reduce panipenem-associated kidney toxicity and prevent panipenem hydrolysis by renal DHP-I^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Betamipron (100 mg/kg; s.c.; once daily; 5 days) as part of a 1:1 panipenem/betamipron formulation results in Clostridium difficile overgrowth in mouse cecal contents by 7 days post-dosing^[1].
Betamipron (250 mg/kg; i.p.; single dose) significantly suppresses Cisplatin (HY-17394)-induced nephrotoxicity in male Wistar rats; significantly reduced Cisplatin-induced weight loss in male ddY mice and decreased serum BUN levels; and did not alter the antileukemic efficacy of cisplatin in male BDF1 mice carrying P388 leukemia^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

ICI strain (male, 5 weeks old, 20g)^[1]
Dosage:

100 mg/kg (as part of a 1:1 panipenem/betamipron formulation)
Administration:

s.c.; once daily; 5 days
Result:

Reduced Clostridium difficile counts in cecal contents to below 10² CFU/g in all 5 mice 1 day after the end of dosing.
Resulted in *Clostridium difficile* counts of 10² CFU/g in 1 mouse and 10³ CFU/g in 4 mice 7 days after the end of dosing.

Animal Model:

Wistar (male, 235-365 g, cisplatin-induced nephrotoxicity model)
ddY (male, 25-32 g, cisplatin-induced nephrotoxicity model)
BDF1 (male, 5 weeks old, 21-24.5 g, P388 leukemia model)
^[2]
Dosage:

250 mg/kg
Administration:

i.p.; single dose (1 hour after cisplatin)
Result:

Blocked cisplatin-induced weight loss, with a 9.37% weight gain versus a 10.8% loss in the cisplatin group. Studies were conducted on male Wistar rats with cisplatin-induced nephrotoxicity.
Decreased serum BUN and creatinine to normal levels, which remained high in rats given cisplatin alone. Studies were conducted on male Wistar rats with cisplatin-induced nephrotoxicity.
Recovered cisplatin-altered water intake, urine volume and pH. Studies were conducted on male Wistar rats with cisplatin-induced nephrotoxicity.
Normalized abnormal urinary biochemical indicators caused by cisplatin. Studies were conducted on male Wistar rats with cisplatin-induced nephrotoxicity.
Mitigated cisplatin-triggered weight loss obviously compared with the combination of cisplatin and alkaline solution. Studies were conducted on male ddY mice with cisplatin-induced nephrotoxicity.
Reduced elevated serum BUN in mice receiving cisplatin plus alkaline solution. Studies were conducted on male ddY mice with cisplatin-induced nephrotoxicity.
Achieved similar survival benefits as cisplatin combined with alkaline solution. Studies were conducted on male BDF1 mice with P388 leukemia.
Extended survival in all cisplatin-treated mice compared with controls. Studies were conducted on male BDF1 mice with P388 leukemia.

Chemical Information

CAS No. 3440-28-6
Appearance Solid
Molecular Weight 193.20
Formula C₁₀H₁₁NO₃
Color White to off-white
SMILES

O=C(O)CCNC(C1=CC=CC=C1)=O
Synonyms

N-Benzoyl-β-alanine
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (517.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.1760 mL

25.8799 mL

51.7598 mL

5 mM

1.0352 mL

5.1760 mL

10.3520 mL

10 mM

0.5176 mL

2.5880 mL

5.1760 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (12.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (12.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (12.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Watanabe K, et al. In vitro antibacterial activity of a new carbapenem, panipenem, against anaerobic bacteria[J]. Chemotherapy, 1991, 39(Suppl 3): 46-54.

[2]. Tokunaga J, et al. Betamipron reduces cisplatin nephrotoxicity in rodents without modifying its antileukemic activity in mice. Ren Fail. 1997;19(3):425-438. [Content Brief]

[3]. El-Gamal MI, et al. Recent updates of carbapenem antibiotics. Eur J Med Chem. 2017;131:185-195. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.1760 mL	25.8799 mL	51.7598 mL	129.3996 mL
	5 mM	1.0352 mL	5.1760 mL	10.3520 mL	25.8799 mL
	10 mM	0.5176 mL	2.5880 mL	5.1760 mL	12.9400 mL
	15 mM	0.3451 mL	1.7253 mL	3.4507 mL	8.6266 mL
	20 mM	0.2588 mL	1.2940 mL	2.5880 mL	6.4700 mL
	25 mM	0.2070 mL	1.0352 mL	2.0704 mL	5.1760 mL
	30 mM	0.1725 mL	0.8627 mL	1.7253 mL	4.3133 mL
	40 mM	0.1294 mL	0.6470 mL	1.2940 mL	3.2350 mL
	50 mM	0.1035 mL	0.5176 mL	1.0352 mL	2.5880 mL
	60 mM	0.0863 mL	0.4313 mL	0.8627 mL	2.1567 mL
	80 mM	0.0647 mL	0.3235 mL	0.6470 mL	1.6175 mL
	100 mM	0.0518 mL	0.2588 mL	0.5176 mL	1.2940 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Betamipron

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Endocrinology Compound Library

Antibacterial Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Human Metabolite Library

Off-patent Drug Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Non-natural Amino Acid Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

MCE Kinase Hinge Binder Fragment Library

All Antibiotic Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Betamipron

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Endocrinology Compound Library

Antibacterial Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Human Metabolite Library

Off-patent Drug Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Non-natural Amino Acid Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

MCE Kinase Hinge Binder Fragment Library

All Antibiotic Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Betamipron Related Classifications

HY-B1127 Related Classifications